UBS Group’s Viking Therapeutics, Inc. VKTXW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-388
| Closed | -$2K | – | 10392 |
|
|
2021
Q1 | $2K | Sell |
388
-1,523
| -80% | -$8.74K | ﹤0.01% | 8728 |
|
|
2020
Q4 | $8K | Buy |
1,911
+64
| +3% | +$292 | ﹤0.01% | 7656 |
|
|
2020
Q3 | $8K | Sell |
1,847
-971
| -34% | -$5.24K | ﹤0.01% | 7073 |
|
|
2020
Q2 | $16K | Buy |
2,818
+146
| +5% | +$770 | ﹤0.01% | 6715 |
|
|
2020
Q1 | $8K | Sell |
2,672
-222
| -8% | -$1.01K | ﹤0.01% | 7110 |
|
|
2019
Q4 | $19K | Sell |
2,894
-800
| -22% | -$4.68K | ﹤0.01% | 6919 |
|
|
2019
Q3 | $20K | Sell |
3,694
-400
| -10% | -$2.36K | ﹤0.01% | 6748 |
|
|
2019
Q2 | $28K | Hold |
4,094
| – | – | ﹤0.01% | 6396 |
|
|
2019
Q1 | $34K | Sell |
4,094
-5,235
| -56% | -$35.7K | ﹤0.01% | 5853 |
|
|
2018
Q4 | $57K | Buy |
9,329
+6,497
| +229% | +$68.1K | ﹤0.01% | 5981 |
|
|
2018
Q3 | $45K | Sell |
2,832
-2,248
| -44% | -$23.5K | ﹤0.01% | 6244 |
|
|
2018
Q2 | $41K | Buy |
5,080
+1,944
| +62% | +$10.2K | ﹤0.01% | 6153 |
|
|
2018
Q1 | $9K | Sell |
3,136
-312
| -9% | -$1.28K | ﹤0.01% | 6963 |
|
|
2017
Q4 | $9K | Buy |
+3,448
| New | +$6.01K | ﹤0.01% | 7119 |
|
|
2017
Q3 | – | Sell |
-232
| Closed | – | – | 8129 |
|
|
2017
Q2 | $0 | Hold |
232
| – | – | ﹤0.01% | 8136 |
|
|
2017
Q1 | $0 | Buy |
+232
| New | +$97 | ﹤0.01% | 8138 |
|
UBS Group's VKTXW Position: Q2 2021 in Review
UBS Group sold out of Viking Therapeutics, Inc. (VKTXW) in Q2 2021, closing a stake of 388 shares — an estimated $2K sold.
UBS Group first reported a position in VKTXW in Q1 2017 and held it in 16 quarters. The position peaked at $57K in Q4 2018. 0 funds tracked by Wall St. Rank hold VKTXW as of Q2 2021.
- UBS Group reported no remaining Viking Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- UBS Group sold 388 Viking Therapeutics, Inc. shares in Q2 2021, an estimated $2K.
- UBS Group first reported a position in Viking Therapeutics, Inc. in Q1 2017 and held it in 16 quarters.
- UBS Group's Viking Therapeutics, Inc. position peaked at $57K in Q4 2018.
- 0 funds tracked by Wall St. Rank held Viking Therapeutics, Inc. as of Q2 2021.
Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.